Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- 12 Nov 2020 Status changed from suspended to discontinued.
- 17 Jul 2018 Status changed from recruiting to suspended.
- 25 Oct 2017 Trial design presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.